BackTeva- Pharmaceutical Industries Overview

Teva- Pharmaceutical Industries Current Assets

Teva- Pharmaceutical Industries's current assets is $14B.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$13.76B
9.03% YoYΔ $1.14B vs prior year quarter

Peer trimmed avg / median

Loading

Teva- Pharmaceutical Industries Current Assets History

Loading

Teva- Pharmaceutical Industries vs. peers: Current Assets Comparison

Loading

Teva- Pharmaceutical Industries Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Teva- Pharmaceutical Industries (TEVA) FAQ

Teva- Pharmaceutical Industries (TEVA) currently reports a current assets of $14B as of June 2026. That compares with $13B in the prior-year period — up 9.0% year over year. Use the charts on this page to explore Teva- Pharmaceutical Industries's current assets history and peer comparisons.

Teva- Pharmaceutical Industries's current assets increased from $13B to $14B — a 9.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Teva- Pharmaceutical Industries reported $14B in current assets as of June 2026. That compares with $13B in the prior-year period — up 9.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current assets of $14B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Teva- Pharmaceutical Industries, and consider following TEVA for alerts when major investors trade the stock.

Teva- Pharmaceutical Industries is classified in the Healthcare sector. On current assets, it currently shows $14B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TEVA with unrelated industries.